Home > Cardiology > AHA 2021 > Heart Failure > Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%

Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%

Presented By
Dr Stefan Anker, Charité University Berlin, Germany
Conference
AHA 2021
Trial
EMPEROR-Preserved
The EMPEROR-Preserved is the first large-scale trial that showed meaningful improvements of a drug therapy in patients with preserved ejection fraction. In a subanalysis of the trial, empagliflozin also demonstrated clinical benefits for heart failure (HF) in patients with left ventricular ejection fraction (LVEF) ≥50%. This result extended to health-related quality of life and symptoms. EMPEROR-Preserved (NCT03057951) evaluated the efficacy and safety of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin compared with placebo in patients with HF with preserved ejection fraction (HFpEF) [1,2]. The trial included 5,988 patients with an LVEF >40%. Dr Stefan Anker (Charité University Berlin, Germany) presented the current analysis, which assessed the subset of included patients with truly preserved EF (≥50%) (n=4,005), in line with the recently upd...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on